Genovis AB (GENO.ST)

Executive Summary

Genovis AB is a Swedish biotechnology company specializing in enzyme-based tools for the research, development, and manufacturing of biologic drugs, particularly monoclonal antibodies. Its flagship SmartEnzymes platform provides engineered enzymes for antibody digestion, fragmentation, and analysis, enabling critical workflows in drug discovery, quality control, and process development. The company serves pharmaceutical and biotech firms, as well as academic institutions, supporting the development of antibody-drug conjugates (ADCs), bispecific antibodies, and other next-generation biologics. Listed on Nasdaq Stockholm, Genovis operates globally through direct sales and a distributor network, with a focus on therapeutic areas such as oncology, immunology, and autoimmune diseases. Genovis holds a niche yet essential position in the bioprocessing value chain, benefiting from the growing demand for biologic drugs and advanced antibody formats. The company's products are integral to the characterization and production of complex therapeutics, driving recurring revenue from established customers and potential adoption by new clients. While the market is competitive, Genovis's proprietary enzyme engineering and strong IP position the company for steady growth. Key opportunities include expanding its product portfolio, securing strategic partnerships with major pharmaceutical companies, and capitalizing on the increasing complexity of biologic drugs. The company's financial performance is supported by a global customer base and a trend toward outsourcing in biologics development.

Upcoming Catalysts (preview)

• Q3 2026Launch of new SmartEnzymes product for ADC development70% success
• Q4 2026Strategic partnership with a top-10 pharmaceutical company50% success
• Q1 2027Expansion into Chinese biotech market via distributor agreement60% success